Company Announcements and Press Releases

Novo Nordisk country sites USA Argentina Australia Austria Belgium Brazil Bulgaria Canada Chile China Croatia Czech Republic Denmark Egypt Estonia Finland France Germany Greece Hungary Iraq Ireland Israel Italy Japan Korea (Republic) Latvia Lebanon Lithuania Mexico Netherlands New Zealand Norway Pakistan Poland Portugal Romania Russian Federation Serbia Slovak Republic Slovenia South Africa Spain Sweden Switzerland Syria Taiwan Thailand Turkey Ukraine United Kingdom Other Novo Nordisk sites Changing diabetes DAWN study Hagedorn Research Institute Diabetes4Patients Diabetes Barometer Changing diabetes bus Media prize World diabetes day School challenge Improve Control HRT for HCPs HRT for women HRT congresses & symposia

• News
• Facts about Novo Nordisk
• R&D pipeline
• Download centre
• Diabetes dictionary
• Broadcast room
• Photos
• Subscription
• Victoza® (liraglutide) press room
• Contact

• 
• Print

News

Total number of voting rights and share capital in Novo Nordisk A/S as of 30 June 2009. (30 June 2009)

Read the full announcement in PDF-format

In accordance with Section 6 of the Danish Statutory Order on Issuers Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk as per the end of the month where changes have occurred.

For further information please contact:

Media:	Investors:
Outside North America:	Outside North America:
Elin K Hansen	Mads Veggerby Lausten
Tel: (+45) 4442 3450	Tel: (+45) 4443 7919
ekh@novonordisk.com	mlau@novonordisk.com
	Kasper Roseeuw Poulsen
	Tel: (+45) 4442 4471
	krop@novonordisk.com
In North America:	In North America:
Sean Clements	Hans Rommer
Tel: (+1) 609 514 8316	Tel: (+1) 609 919 7937
secl@novonordisk.com	hrmm@novonordisk.com

Company Announcement no 38 / 2009